Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics halts AlloNK development, cuts 94% of workforce, explores sale

Negative Impact 5 of 5 restructuring Written later

Artiva Biotherapeutics will stop developing its lead candidate AlloNK after updated data showed durability of clinical response did not meet its required threshold, and two Grade 5 safety events occurred in its trials. The company is reducing its workforce by about 94% and exploring strategic alternatives, including a merger, sale or licensing of assets, or dissolution and liquidation, which could affect the value returned to shareholders.

Key points

  • Preliminary cash, cash equivalents and investments were about $319.1 million as of September 30, 2026 (unaudited)
  • Workforce reduction of about 94% expected to be completed in the first quarter of 2027; a significant majority of Wind Down costs expected in Q4 2026
  • Total Wind Down costs cannot be reasonably estimated at this time
  • Leerink Partners engaged as financial advisor; planned Phase 3 trial will not be initiated

The filing

CompanyArtiva Biotherapeutics, Inc. (ARTV)
Form8-K, current report
Filed with the SECOct 27, 2026, 8:30 AM ET
Accession number0001193125-26-432806

Items reported: 2.02 Results of Operations2.05 Exit / Restructuring Costs

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.